Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C38685
http://purl.obolibrary.org/obo/NCIT_C38685
|
|---|---|
| Preferred Name | Siplizumab |
| Definitions |
A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. |
|---|---|
| prefLabel | Siplizumab
|
| label | Siplizumab
|
| PDQ_Closed_Trial_Search_ID | 346499
|
| code | C38685
|
| prefixIRI | NCIT:C38685
|
| in_subset | |
| Preferred_Name | Siplizumab
|
| FDA_UNII_Code | KUW1QG1ZM3
|
| Contributing_Source | FDA
|
| Maps_To | Siplizumab
|
| CAS_Registry | 288392-69-8
|
| NCI_Drug_Dictionary_ID | 346499
|
| Legacy Concept Name | Siplizumab
|
| type | |
| ALT_DEFINITION | A monoclonal antibody that is being studied in the treatment of certain lymphoproliferative disorders and psoriasis.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 346499
|
| Accepted_Therapeutic_Use_For | T-cell lymphoma
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C1328709
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |